Company: SHPH
Filing Date: 2025-02-27
Form Type: 424B3
Source: 0001493152-25-008476
Chunk: 126

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-27
Form: 424B3
Chunk 126
---
 environment, management is currently implementing additional measures which include:

| ● | Hired                                                                                                                          
 a new Chief Financial Officer during the second quarter of 2024 to bolster the Company’s internal technical accounting and     
 financial reporting experience and provide bandwidth for the prior Chief Financial Officer to focus on the Company’s expanding 
 clinical trial.                                                                                                                |
| ● | Engaged                                                                                                                        
 a third-party consulting firm to assist with the preparation of SEC reporting and other technical accounting matters.          |

The
Company will continue to review and improve its internal controls over financial reporting to address the underlying causes of the material
weaknesses and control deficiencies. While the Company has added significant resources, particularly relevant to unusual and complex
accounting matters, and stock-based compensation accounting and reporting, its material weaknesses and control deficiencies will not
be fully remediated until the Company has concluded that its internal controls are operating effectively for a sufficient period of time.

Item 9B. Other Information

None.

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Not applicable.

| 69 |

<div align='center'>PART III</div>

Item 10. Directors, Executive Officers and Corporate Governance

<div align='center'>MANAGEMENT</div>

Our directors and executive officers and their respective ages and titles are as follows:

| Name                 |     | Age |     | Position(s)                                                   
 and Office(s) Held                                            |
| Anatoly              
 Dritschilo, M.D.     |     |  80 |     | Chairman                                                      
 of the board of directors and Chief Executive Officer         |
| Timothy              
 J. Lorber            |     |  67 |     | Chief                                                         
 Financial Officer                                             |
| Michael              
 Vander Hoek          |     |  65 |     | VP                                                            
 for Operations and Regulatory, former Chief Financial Officer |
| Peter                
 Dritschilo           |     |  55 |     | President                                                     
 and Chief Operating Officer                                   |
| Mira                 
 Jung, Ph.D.          |     |  75 |     | Chief                                                         
 Scientific Officer                                            |
| Tyvin                
 Rich, M.D.           |     |  77 |     | Chief                                                         
 Clinical Officer                                              |
| Milton               
 Brown, M.D., Ph.D.   |     |  59 |     | Director                                                      |
| Steven               
 Richards             |     |  56 |     | Independent                                                   
 Director (1)(2)(3)                                            |
| Joshua               
 Schafer